roche

Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma

pharmafile | December 16, 2019 | News story | Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq 

Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when combined with Cotellic (cobimetinib) and Zelboraf (vemurafenib), met its primary endpoint in the treatment of previously untreated BRAF V600 mutation-positive advanced melanoma.

While specifics of the findings were not revealed, Roche confirmed that the combo generated a “significant and clinically meaningful” improvement in progression-free survival (PFS) compared to placebo plus Cotellic and Zelboraf.

The company also confirmed that the full details of the findings would be presented at an upcoming medical meeting, and that they will also help form the basis for regulatory submissions with the FDA and EMA.

“By combining a cancer immunotherapy with targeted therapies, we hope to offer a new approach that improves outcomes for people with advanced, BRAF-mutant melanoma,” commented Dr Levi Garraway, Chief Medical Officer and Head of Global Product Development at Roche. “We look forward to discussing the results with health authorities around the world.”

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Latest content